Unichem Laboratories Limited announced that it has received ANDA approval for its Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Ranexa®? (ranolazine extended-release tablets) 500 mg and 1,000 mg, of Gilead Sciences Inc. Ranolazine Extended-Release Tablets, 500 mg, and 1,000 mg are indicated for the treatment of chronic angina. The product will be commercialized from Unichem's Goa Plant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
544.8 INR | +2.80% | +0.51% | +33.90% |
1st Jan change | Capi. | |
---|---|---|
+33.90% | 459M | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- UNICHEMLAB Stock
- News Unichem Laboratories Limited
- Unichem Laboratories Limited Receives ANDA Approval for its Ranolazine Extended-Release Tablets, 500 Mg and 1,000 Mg from the United States Food and Drug Administration